



PRESS RELEASE

Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region

Lyon, France, November 18th, 2015 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins, especially insulins for diabetes treatment, announces that it received the “Listed Company” prize for the Grand Rhône-Alpes region during the 15th Deloitte In Extenso Technology Fast 50 event in Lyon.

The Technology Fast 50 program was founded in 1995 in San Jose, California, then extended to more than 40 countries. Every year, it promotes and recognizes companies combining technological innovation and fast growth.

Adocia was awarded the “Listed Company” prize for the very strong increase of its annual turnover between the years 2011 and 2014. The year 2014 was marked by the 570 million dollars license agreement which grants Eli Lilly and Company worldwide rights on BioChaperone Lispro, the ultra-rapid insulin formulation developed by Adocia. This significant turnover increase was associated with a surge of Adocia share’s value of more than 500% over the three years following its quotation.

“Two years after receiving the « Biotech d’Avenir Deloitte Technology Fast 50 » prize, our team can be very proud of this new mark of recognition.” comments Gérard Soula, Chief Executed Officer of Adocia. “The “Listed Company” prize rewards our innovation strategy, which aims to deliver more efficient, affordable therapeutic solutions for each population of diabetic patients.”

A propos d’ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100) and a combination of insulin

glargine and a fast-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com

About Technology Fast 50 program

The Technology Fast 50 program started in 1995 in San Jose, California, at the heart of the Silicon Valley, and was then extended to the United States and then to the United Kingdom, Canada, the Netherlands, Israel and France. It is now present in more than 40 countries and regions around the world. It was created in order to recognize the outstanding contribution of technological companies to the growth of the economy.

Deloitte has also developed three continental competitions:

Europe, Middle East and Africa : Fast 500 EMEA

North America : Fast 500 North America

Asia Pacific : Fast 500 Asia Pacific.

To learn more, visit www.fast50france.com

About Deloitte

Deloitte refers to one or more member firms of Deloitte Touche Tohmatsu Ltd, a UK private company limited by guarantee ("DTTL") and its network of member firms, each of which is a legally separate and independent entity. To learn more about the legal structure of Deloitte Touche Tohmatsu Ltd and its member firms, visit www.deloitte.com/about. In France, Deloitte SAS is the member firm of Deloitte Touche Tohmatsu Ltd, and the professional services are provided by its subsidiaries and affiliates.

About In Extenso

In Extenso, member of Deloitte, is a key accounting firm in France. With a network of more than 4 500 collaborators and 220 agencies spread over the territory, In Extenso proposes to entrepreneurs, artisans, retail traders, liberal professions and association managers full professional services, favoring proximity, listening to clients and proactivity. Deeply embedded into the French economic fabric, In Extenso is the privileged interlocutor of more than 90 000 customers belonging to all areas of activities. In Extenso realized in 2014-2015 a turnover of 360 million euros. To discover more, visit www.inextenso.fr and www.reussir-au-quotidien.fr



For more information please contact:

Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Tel.: +33 4 72 610 610	Adocia Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie caroline@alizerp.com adocia@alizerp.com Tel.: + 33 1 44 54 36 61	Deloitte Press Relations Julia Debiegne PR Deloitte Tél. : + 33 1 55 61 41 69 jdebienne@deloitte.fr
---	--	--

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 'Risk Factors' section of the Reference Document registered by the French Autorité des marchés financiers on April 30, 2015 under number R.15-032 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.